Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 2579
Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 2515
Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2206
Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis
Imaging of Rheumatic Diseases Poster III: Other Modalities- 9:00AM-11:00AM
-
Abstract Number: 2011
Juvenile Arthritis-Associated Single Nucleotide Polymorphisms Identified on Whole Genome Sequencing Show Enrichment within H3K9me3-Marked Regions
Pediatric Rheumatology – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 2087
Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 2196
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Imaging of Rheumatic Diseases Poster III: Other Modalities- 9:00AM-11:00AM
-
Abstract Number: 2055
Laser Capture Microdissection to Interrogate B Cells in RA Synovial Tissue
Rheumatoid Arthritis – Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2747
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: 1973
Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 1970
Linking Genetics to T Cell Phenotype in JIA: Rationale for IL-2 Therapy
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 2447
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2529
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2234
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 2290
Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel